Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

AIM To determine the effect of combined serelaxin and rosiglitazone treatment on established hepatic fibrosis. METHODS Hepatic fibrosis was induced in mice by carbon tetrachloride administration for 6 wk, or vehicle alone (nonfibrotic mice). For the final 2 wk, mice were treated with rosiglitazone, serelaxin, or both rosiglitazone and serelaxin. Serum liver enzymes and relaxin levels were determined by standard methods. The degree of liver collagen content was determined by histology and immunohistochemistry. Expression of type I collagen was determined by quantitative PCR. Activation of hepatic stellate cells was assessed by alpha-smooth muscle actin (SMA) levels. Liver peroxisome proliferator activated receptor-gamma coactivator 1 alpha (PGC1α) was determined by Western blotting. RESULTS Treatment of mice with CCl4 resulted in hepatic fibrosis as evidenced by increased liver enzyme levels (ALT and AST), and increased liver collagen and SMA. Monotherapy with either serelaxin or rosiglitazone for 2 wk was generally without effect. In contrast, the combination of serelaxin and rosiglitazone resulted in significantly improved ALT levels (P < 0.05). Total liver collagen content as determined by Sirius red staining revealed that only combination treatment was effective in reducing total liver collagen (P < 0.05). These results were supported by immunohistochemistry for type I collagen, in which only combination treatment reduced fibrillar collagen levels (P < 0.05). The level of hepatic stellate cell activation was modestly, but significantly, reduced by serelaxin treatment alone, but combination treatment resulted in significantly lower SMA levels. Finally, while hepatic fibrosis reduced liver PGC1α levels, the combination of serelaxin and rosiglitazone resulted in restoration of PGC1α protein levels. CONCLUSION The combination of serelaxin and rosiglitazone treatment for 2 wk was effective in significantly reducing established hepatic fibrosis, providing a potential new treatment strategy.

Original languageEnglish (US)
Pages (from-to)3999-4006
Number of pages8
JournalWorld Journal of Gastroenterology
Volume23
Issue number22
DOIs
StatePublished - Jun 14 2017

Fingerprint

rosiglitazone
Fibrosis
Liver
Collagen
Smooth Muscle
Actins
Hepatic Stellate Cells
Therapeutics
Collagen Type I
Immunohistochemistry
Fibrillar Collagens

Keywords

  • Fibrosis
  • Liver cirrhosis
  • Liver diseases
  • Peroxisome proliferator-activated receptors
  • Relaxin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis. / Bennett, Robert G; Simpson, Ronda L.; Hamel, Frederick G.

In: World Journal of Gastroenterology, Vol. 23, No. 22, 14.06.2017, p. 3999-4006.

Research output: Contribution to journalArticle

@article{da7c1833d2ed40a49621b12b54f85e9b,
title = "Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis",
abstract = "AIM To determine the effect of combined serelaxin and rosiglitazone treatment on established hepatic fibrosis. METHODS Hepatic fibrosis was induced in mice by carbon tetrachloride administration for 6 wk, or vehicle alone (nonfibrotic mice). For the final 2 wk, mice were treated with rosiglitazone, serelaxin, or both rosiglitazone and serelaxin. Serum liver enzymes and relaxin levels were determined by standard methods. The degree of liver collagen content was determined by histology and immunohistochemistry. Expression of type I collagen was determined by quantitative PCR. Activation of hepatic stellate cells was assessed by alpha-smooth muscle actin (SMA) levels. Liver peroxisome proliferator activated receptor-gamma coactivator 1 alpha (PGC1α) was determined by Western blotting. RESULTS Treatment of mice with CCl4 resulted in hepatic fibrosis as evidenced by increased liver enzyme levels (ALT and AST), and increased liver collagen and SMA. Monotherapy with either serelaxin or rosiglitazone for 2 wk was generally without effect. In contrast, the combination of serelaxin and rosiglitazone resulted in significantly improved ALT levels (P < 0.05). Total liver collagen content as determined by Sirius red staining revealed that only combination treatment was effective in reducing total liver collagen (P < 0.05). These results were supported by immunohistochemistry for type I collagen, in which only combination treatment reduced fibrillar collagen levels (P < 0.05). The level of hepatic stellate cell activation was modestly, but significantly, reduced by serelaxin treatment alone, but combination treatment resulted in significantly lower SMA levels. Finally, while hepatic fibrosis reduced liver PGC1α levels, the combination of serelaxin and rosiglitazone resulted in restoration of PGC1α protein levels. CONCLUSION The combination of serelaxin and rosiglitazone treatment for 2 wk was effective in significantly reducing established hepatic fibrosis, providing a potential new treatment strategy.",
keywords = "Fibrosis, Liver cirrhosis, Liver diseases, Peroxisome proliferator-activated receptors, Relaxin",
author = "Bennett, {Robert G} and Simpson, {Ronda L.} and Hamel, {Frederick G}",
year = "2017",
month = "6",
day = "14",
doi = "10.3748/wjg.v23.i22.3999",
language = "English (US)",
volume = "23",
pages = "3999--4006",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "22",

}

TY - JOUR

T1 - Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis

AU - Bennett, Robert G

AU - Simpson, Ronda L.

AU - Hamel, Frederick G

PY - 2017/6/14

Y1 - 2017/6/14

N2 - AIM To determine the effect of combined serelaxin and rosiglitazone treatment on established hepatic fibrosis. METHODS Hepatic fibrosis was induced in mice by carbon tetrachloride administration for 6 wk, or vehicle alone (nonfibrotic mice). For the final 2 wk, mice were treated with rosiglitazone, serelaxin, or both rosiglitazone and serelaxin. Serum liver enzymes and relaxin levels were determined by standard methods. The degree of liver collagen content was determined by histology and immunohistochemistry. Expression of type I collagen was determined by quantitative PCR. Activation of hepatic stellate cells was assessed by alpha-smooth muscle actin (SMA) levels. Liver peroxisome proliferator activated receptor-gamma coactivator 1 alpha (PGC1α) was determined by Western blotting. RESULTS Treatment of mice with CCl4 resulted in hepatic fibrosis as evidenced by increased liver enzyme levels (ALT and AST), and increased liver collagen and SMA. Monotherapy with either serelaxin or rosiglitazone for 2 wk was generally without effect. In contrast, the combination of serelaxin and rosiglitazone resulted in significantly improved ALT levels (P < 0.05). Total liver collagen content as determined by Sirius red staining revealed that only combination treatment was effective in reducing total liver collagen (P < 0.05). These results were supported by immunohistochemistry for type I collagen, in which only combination treatment reduced fibrillar collagen levels (P < 0.05). The level of hepatic stellate cell activation was modestly, but significantly, reduced by serelaxin treatment alone, but combination treatment resulted in significantly lower SMA levels. Finally, while hepatic fibrosis reduced liver PGC1α levels, the combination of serelaxin and rosiglitazone resulted in restoration of PGC1α protein levels. CONCLUSION The combination of serelaxin and rosiglitazone treatment for 2 wk was effective in significantly reducing established hepatic fibrosis, providing a potential new treatment strategy.

AB - AIM To determine the effect of combined serelaxin and rosiglitazone treatment on established hepatic fibrosis. METHODS Hepatic fibrosis was induced in mice by carbon tetrachloride administration for 6 wk, or vehicle alone (nonfibrotic mice). For the final 2 wk, mice were treated with rosiglitazone, serelaxin, or both rosiglitazone and serelaxin. Serum liver enzymes and relaxin levels were determined by standard methods. The degree of liver collagen content was determined by histology and immunohistochemistry. Expression of type I collagen was determined by quantitative PCR. Activation of hepatic stellate cells was assessed by alpha-smooth muscle actin (SMA) levels. Liver peroxisome proliferator activated receptor-gamma coactivator 1 alpha (PGC1α) was determined by Western blotting. RESULTS Treatment of mice with CCl4 resulted in hepatic fibrosis as evidenced by increased liver enzyme levels (ALT and AST), and increased liver collagen and SMA. Monotherapy with either serelaxin or rosiglitazone for 2 wk was generally without effect. In contrast, the combination of serelaxin and rosiglitazone resulted in significantly improved ALT levels (P < 0.05). Total liver collagen content as determined by Sirius red staining revealed that only combination treatment was effective in reducing total liver collagen (P < 0.05). These results were supported by immunohistochemistry for type I collagen, in which only combination treatment reduced fibrillar collagen levels (P < 0.05). The level of hepatic stellate cell activation was modestly, but significantly, reduced by serelaxin treatment alone, but combination treatment resulted in significantly lower SMA levels. Finally, while hepatic fibrosis reduced liver PGC1α levels, the combination of serelaxin and rosiglitazone resulted in restoration of PGC1α protein levels. CONCLUSION The combination of serelaxin and rosiglitazone treatment for 2 wk was effective in significantly reducing established hepatic fibrosis, providing a potential new treatment strategy.

KW - Fibrosis

KW - Liver cirrhosis

KW - Liver diseases

KW - Peroxisome proliferator-activated receptors

KW - Relaxin

UR - http://www.scopus.com/inward/record.url?scp=85020531438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020531438&partnerID=8YFLogxK

U2 - 10.3748/wjg.v23.i22.3999

DO - 10.3748/wjg.v23.i22.3999

M3 - Article

C2 - 28652653

AN - SCOPUS:85020531438

VL - 23

SP - 3999

EP - 4006

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 22

ER -